论文部分内容阅读
目的研究头孢曲松/舒巴坦(CRO/SBT)及CRO单剂对四川地区临床分离致病菌的体外抗菌活性。方法采用琼脂二倍稀释法测定263株临床分离致病菌的最低抑菌浓度(MIC),观察细菌接种量、培养基pH及血清蛋白含量对体外抗菌活性的影响。结果 CRO/SBT联用可使金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌、大肠埃希菌(产ESBLs)、铜绿假单胞菌、阴沟肠杆菌、肺炎克雷伯菌(产ESBLs)和鲍曼不动杆菌从单用CRO的MIC50值64～>256 mg.L-1降至4～32 mg.L-1,降幅达8～16倍。结论 CRO/SBT联合配伍使用的抗菌效果优于单用,CRO/SBT(4∶1)配方为较合理的复方制剂。
Objective To study the in vitro antibacterial activity of ceftriaxone / sulbactam (CRO / SBT) and CRO single agents against clinically isolated pathogens in Sichuan Province. Methods The minimum inhibitory concentration (MIC) of 263 clinically isolated pathogens was determined by agar dilution method. The effects of inoculation amount, medium pH and serum protein content on the antibacterial activity in vitro were observed. Results The combination of CRO / SBT could induce Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli (ESBLs), Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella pneumoniae (ESBLs producing) and Acinetobacter baumanii decreased 8 ~ 16 times from 64 ~> 256 mg.L-1 of CRO to 4 ~ 32 mg.L-1. Conclusion The combination of CRO / SBT with antibacterial effect is superior to single use, CRO / SBT (4: 1) formula is more reasonable compound.